Longeveron (LGVN) announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company’s overall business strategy, Alzheimer’s disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome program. Prior to Longeveron, Powell led Corporate Development & Strategy for Surescripts
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGVN:
- Positive Buy Rating for Longeveron Driven by Phase 2b Study Milestone and Favorable Market Conditions
- Longeveron completes enrollment of Phase 2b trial of laromestrocel in HLHS
- Longeveron Elects New Director at Annual Meeting
- Longeveron management to meet with Roth MKM
- Buy Rating for Longeveron: ELPIS II Trial Progress and Financial Stability Highlighted